

Sernova Company Overview

Founded: 2006, TSX(V) "SVA.V" ; www.sernova.com

Sernova Corp is a London, Ontario based clinical stage company, developing disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova's primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, hemophilia A and thyroid disease.

Sernova's novel approach uses therapeutic cells placed into an implanted medical device to produce proteins or hormones which are in short supply or missing from the body due to the underlying disease state. The **Cell Pouch System™**, is an implantable, scalable medical device about the size of a business card which provides a natural "organ-like" environment for the long-term survival and function of therapeutic cells such as insulin producing islets to treat diabetes. Unlike other implantable devices, Sernova's **Cell Pouch™** is specifically designed and proven to incorporate with vascularized tissue eliminating the concern of fibrosis. The **Therapeutic Cells** placed into the device may be natural (human) donor cells, or cells that can be a source to treat millions of patients including stem cell derived insulin responsive cells or xenogeneic cells. Sernova uses proprietary **local immune protection technologies** which protect therapeutic cells within the Cell Pouch™ from immune system attack reducing or eliminating the need for daily anti-rejection drugs. Sernova's approach is designed to make future therapeutic cell replacement a simple outpatient procedure that can be performed in virtually any hospital setting. Using a medical device and therapeutic cell strategy to treat chronic diseases, Sernova is positioned for significant revenue upon commercialization of its "disruptive paradigm-shifting" platform technology.

Sernova's team is focused on development of the Cell Pouch System™ for diabetes to treat both Type-1 and Type-2 patients who become insulin dependent –representing a treatable population of an estimated 40M patients worldwide currently taking insulin. Sernova is also focused on development of the Cell Pouch System™ for the treatment of Hemophilia A through use of cells placed in the Cell Pouch™ which release Factor VIII at a constant rate.

TECHNOLOGY HIGHLIGHTS

- **The Standard of Care** for patients with reduced or missing critical hormones or proteins such as insulin is often monitoring blood levels and injecting these proteins multiple times a day with a consequence of poor compliance and serious side effects resulting in over \$150B/yr hospital costs for diabetes alone. Cell therapy is an alternative for patients with chronic diseases; however, there is no currently approved device to house and protect these cells in the body and no method to make the therapy a simple outpatient procedure. Instead, often cells are injected multiple times into blood vessels in an extremely expensive (>\$100,000) and risky procedure, where many cells die through blood-derived inflammation and clotting, resulting in the need for repeat operations. Hence, the current standard of care for local cell therapy is limited by expensive procedures, poor cell survival and inappropriate delivery coupled with a lack of donors.
- **Sernova's Cell Pouch System™** is a versatile, scalable implantable medical device made of materials approved for permanent use in the body, designed by biomedical engineers and biologists. Placed under the skin or in other locations, it develops organ-like characteristics (including vascularization) for survival and long term function of therapeutic cells. A natural environment where therapeutic cells are housed within a non-fibrotic tissue matrix, rich in microvessels is expected to conserve cell number, and promote natural function - increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.
- **Sernova's Therapeutic Cell** technologies involve the use of natural donor cells, stem cell derived insulin responsive cells or xenogeneic cells to replace cells in the body that no longer produce the therapeutic proteins.
- **Sernova's Local Immune Protection Technologies** placed within the Cell Pouch™ with therapeutic cells is expected to eliminate the need for systemically administered toxic and expensive anti-rejection drugs (\$10-15,000/yr).

FIRST THERAPEUTIC APPLICATION - DIABETES

The Cell Pouch™ has been contract manufactured in accordance with the strict guidelines of ISO13485, as mandated by the FDA. In preclinical safety and efficacy studies, the Cell Pouch™ with islets has been shown to be safe and to control sugar levels in small

This document may contain forward looking statements. Forward looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The inclusion of such information does not imply that Sernova Corp. endorses or accepts any responsibility for the content or use of such information.

Copyright 2016, Sernova Corp.

Sernova Corp.

Stiller Centre
700 Collip Circle
London, ON, Canada
N6G 4X8

President and CEO
Dr. Philip Toleikis
Tel: + 1 604-961-2939



(isograft – similar cell transplants) and large animal transplantation models of diabetes including an autograft model (self-islets are placed into the Cell Pouch™) and an allograft model (donor islets are placed into the Cell Pouch™). Sernova’s technologies have been independently proven under collaboration with Dr. James Shapiro (University of Alberta, Edmonton) in a marginal islet mass study showing that a small dose of islets can make diabetic animals insulin independent at the 100 day time point. Several of Sernova’s important preclinical studies have been funded in part by agencies such as the National Research Council (IRAP) of Canada. In addition to these studies, the Cell Pouch™ has been shown to be biocompatible in a series of FDA mandated preclinical studies (ISO10993).

Sernova Corp. received Health Canada Approval to conduct a Phase I/II human clinical trial assessing the safety of Sernova's Cell Pouch™ with transplanted insulin-producing islets in patients with insulin-dependent diabetes. The primary endpoint of safety and biocompatibility has been demonstrated and presented at the International Pancreas and Islet Transplantation Association and at the 2015 American Diabetes Association Meeting. Based on these positive results, Sernova has received a grant of \$US2.4M from the Juvenile Diabetes Research Foundation to continue clinical studies in the United States, expected to begin enrolling patients in 2017.

ADDITIONAL PRODUCT OPPORTUNITIES/PARTNERING/M&A

While in this initial clinical study, subjects receive the latest antirejection medications to protect the islets, Sernova plans to conduct additional trials using its local immune protection technologies. Furthermore, with the success of the Cell Pouch™ to date, Sernova has gained worldwide rights to a glucose responsive, insulin producing stem cell derived technology licensed from University Health Network (University of Toronto) renowned Drs. Gordon Keller and Cristina Nostro to provide an unlimited supply of cells for the treatment of diabetes. Sernova is also actively pursuing additional technologies to provide further unlimited sources of locally immune protected cells including stem cell derived insulin responsive cells and xenogeneic cells to treat the 40M patients currently taking insulin worldwide.

The Company is currently also developing products for Hemophilia A. It is a (corporate) member of a European Consortium (HemAcure) which has received approximately 5.6M EU (\$8.5M CAD) funding from the European Union with a successful, highly prestigious European Union Horizon 2020 grant. The grant is to develop the product for clinical trials in patients with Hemophilia A and is expected to reduce or eliminate the need for multiple weekly infusions of Factor VIII. It is also planning development of an allograft product. The current market for Factor VIII which must be infused thrice weekly for prophylactic treatment is approximately \$5.0B/yr. Sernova plans to develop other indications using the Cell Pouch System™ to treat diseases such as Thyroid disease, with approximately 250,000 patients/yr who could benefit from a cell therapy approach. Sernova is seeking corporate partners for these therapies and plans to in-license additional complementary technologies.

INVESTOR VALUE PROPOSITION AND EXIT STRATEGY

The table below shows a comparison of diabetes technologies. Sernova’s Cell Pouch System™ technology platform is unique to anything currently on the market or in development. This has generated strong interest from potential pharmaceutical corporate partners.

Sernova’s Cell Pouch™ Offers a Unique Investment Proposition vs. Other MedTech Diabetes Management Programs

	Endogenous Insulin Production	Internal, Self-contained	Number of Components	Human Insulin	Developmental Stage
Sernova - Cell Pouch™	✓	✓	1	✓	Ph. I/II
Insulin Pumps	✗	✗	6	✗ / ✓	Marketed

SERNOVA’S BOARD of DIRECTORS

Stellar Management Team: President and CEO since May 2009 – Dr. Philip Toleikis: Former VP Pharmacology R&D, Angiotech Pharmaceuticals, where he was part of the team that developed the multi-billion dollar drug-eluting stent and other drug-eluting medical devices. Our management team has over 20 years experience.

Board of Directors: Chairman Frank Holler – CEO and partner BC Advantage Funds; Jeffery Bacha – CEO Delmar Pharmaceuticals, Inc.; Bruce Weber – Previous V.P Clinical, Regulatory and QA Innovia LLC; James Parsons, CA, CFO Trillium Therapeutics; Dr. Philip Toleikis, President and CEO Sernova Corp.

Company Contacts: Dr. Philip Toleikis – President & CEO; philip.toleikis@sernova.com; Cell: 604-961-2939;
Ray Matthews: Ray Matthews, Inc. ray@raymatthews.ca; Cell: 604-818-7778.